Eli Lilly starts late-stage study of arthritis drug in COVID-19 patients

U.S. drugmaker Eli Lilly and Co said on Monday it has started a late-stage trial testing its rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.